Recent developments in the management of invasive fungal infections in patients with hematological malignancies

被引：31

作者：

Karthaus, M

Cornely, O

机构：

[1] Evangel Johannes Krankenhaus, Med Klin 2, D-33611 Bielefeld, Germany

[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany

来源：

ANNALS OF HEMATOLOGY | 2005年 / 84卷 / 04期

关键词：

invasive fungal infection; Aspergillosis; antigen assay; antifungals; azoles; echinocandins; Candida; infection;

D O I：

10.1007/s00277-004-0986-0

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Despite recent advances in the last decade, invasive fungal infections are still associated with a high morbidity and mortality. Invasive fungal infections constitute severe infectious complications in patients with hematological malignancies receiving myelosuppressive chemotherapy or sustained immunosuppression after allogeneic transplant regimens. Following a long period of stagnation, considerable progress has been made during the last 5 years in non-culture-based diagnostics and in the treatment of invasive fungal infections. This review highlights recent developments in the epidemiology, diagnosis, and treatment in the context of state-of-the-art management of invasive fungal infections in cancer patients.

引用

页码：207 / 216

页数：10

共 58 条

[1]

ALMYROUDIS N, 2003, 43 ICAAC ABSTR AM SO, P457

[2] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[3]

BISCHOFF TR, 2003, 43 ICAAC ABSTR AM SO, P348

[4] Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy - A randomized, controlled trial [J].

Boogaerts, M ;

Winston, DJ ;

Bow, EJ ;

Garber, G ;

Reboli, AC ;

Schwarer, AP ;

Novitzky, N ;

Boehme, A ;

Chwetzoff, E ;

De Beule, K .

ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) :412-422

[5] Antifungal prophylaxis for severely neutropenic chemotherapy recipients -: A meta-analysis of randomized-controlled clinical trials [J].

Bow, EJ ;

Laverdiére, M ;

Lussier, N ;

Rotstein, C ;

Cheang, MS ;

Ioannou, S .

CANCER, 2002, 94 (12) :3230-3246

[6]

BUCHHEIDT D, 2003, 43 ICAAC ABSTR AM SO, P478

[7] Treatment of severe Candida infections in high-risk patients in Germany:: Consensus formed by a panel of interdisciplinary investigators [J].

Büchner, T ;

Fegeler, W ;

Bernhardt, H ;

Brockmeyer, N ;

Duswald, KH ;

Herrmann, M ;

Heuser, D ;

Jehn, U ;

Just-Nübling, G ;

Karthaus, M ;

Maschmeyer, G ;

Müller, FM ;

Müller, J ;

Ritter, J ;

Roos, N ;

Ruhnke, M ;

Schmalreck, A ;

Schwarze, R ;

Schwesinger, G ;

Silling, G .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2002, 21 (05) :337-352

[8] Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies [J].

Cornely, OA ;

Ullmann, AJ ;

Karthaus, M .

BLOOD, 2003, 101 (09) :3365-3372

[9]

CORNELY OA, 2003, 43 ICAAC ABSTR AM SO, P456

[10] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

← 1 2 3 4 5 6 →